Specific Biologic Therapy with Tumor Necrosis Factor Inhibitors in Patients with Inflammatory Myopathy

Author(s): Moises Labrador-Horrillo, Miquel V. Tarres

Journal Name: Current Rheumatology Reviews

Volume 1 , Issue 2 , 2005

Become EABM
Become Reviewer


Tumor necrosis factor (TNF) and TNF receptors are members of a family of molecules with important regulatory functions that include cellular activation and apoptosis. Neutralization of TNFa has proven to be effective in a variety of inflammatory disorders and autoimmune diseases such as rheumatoid arthritis and Crohns disease. Treatment of inflammatory myopathies remains a challenge, especially in the case of refractory disease. Elevation of soluble tumor necrosis factor observed in patients with polymyositis/dermatomyositis has led to the suggestion that biologic therapies may be useful in these patients, although experience with anti-TNF agents is still limited. The aim of this mini-review is to summarize the biological bases for treatment of these patients with TNFα inhibitors, to look at the risks and benefits of this therapy -malignancy in patients with a recognized paraneoplastic association and infection versus therapeutic response in refractory myositisand to review the results of the currently reported cases.

Keywords: polymyositis, dermatomyositis, inflammatory myopathies, infliximab, etarnecept, tumor necrosis factor a inhibitors

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [157 - 165]
Pages: 9
DOI: 10.2174/1573397054023173
Price: $65

Article Metrics

PDF: 3